Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors.


Journal

Endocrine-related cancer
ISSN: 1479-6821
Titre abrégé: Endocr Relat Cancer
Pays: England
ID NLM: 9436481

Informations de publication

Date de publication:
01 10 2023
Historique:
received: 13 03 2023
accepted: 02 08 2023
pmc-release: 01 10 2024
medline: 12 9 2023
pubmed: 14 8 2023
entrez: 14 8 2023
Statut: epublish

Résumé

Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms, believed to originate from the interstitial cells of Cajal (ICC), often caused by overexpression of tyrosine kinase receptors (TKR) KIT or PDGFRA. Here, we present evidence that the embryonic stem cell factor FOXD3, first identified as 'Genesis' and involved in both gastrointestinal and neural crest cell development, is implicated in GIST pathogenesis; its involvement is investigated both in vitro and in zebrafish and a mouse model of FOXD3 deficiency. Samples from a total of 58 patients with wild-type GISTs were used for molecular analyses, including Sanger sequencing, comparative genomic hybridization, and methylation analysis. Immunohistochemistry and western blot evaluation were used to assess FOXD3 expression. Additionally, we conducted in vitro functional studies in tissue samples and in transfected cells to confirm the pathogenicity of the identified genetic variants. Germline partially inactivating FOXD3 sequence variants (p.R54H and p.Ala88_Gly91del) were found in patients with isolated GISTs. Chromosome 1p loss was the most frequent chromosomal abnormality identified in tumors. In vitro experiments demonstrate the impairment of FOXD3 in the presence of those variants. Animal studies showed disruption of the GI neural network and changes in the number and distribution in the ICC. FOXD3 suppresses KIT expression in human cells; its inactivation led to an increase in ICC in zebrafish, as well as mice, providing evidence for a functional link between FOXD3 defects and KIT overexpression leading to GIST formation.

Identifiants

pubmed: 37578265
doi: 10.1530/ERC-23-0067
pii: e230067
pmc: PMC10564589
mid: NIHMS1926804
doi:
pii:

Substances chimiques

Stem Cell Factor 0
Proto-Oncogene Proteins c-kit EC 2.7.10.1
Receptor, Platelet-Derived Growth Factor alpha EC 2.7.10.1
Transcription Factors 0
FOXD3 protein, human 0
Forkhead Transcription Factors 0

Banques de données

figshare
['10.6084/m9.figshare.16439055.v1']

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA HD008920
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA101956
Pays : United States

Références

J Physiol. 2008 Feb 15;586(4):1185-94
pubmed: 18096603
J Clin Endocrinol Metab. 2009 Oct;94(10):3656-62
pubmed: 19723753
Development. 2008 May;135(9):1615-24
pubmed: 18367558
J Biol Chem. 1999 Jan 15;274(3):1573-80
pubmed: 9880535
Arch Pathol Lab Med. 2006 Oct;130(10):1466-78
pubmed: 17090188
Am J Pathol. 1998 May;152(5):1259-69
pubmed: 9588894
Genes Chromosomes Cancer. 2022 Jul;61(7):412-419
pubmed: 35170141
Biochim Biophys Acta Mol Cell Res. 2019 Dec;1866(12):118531
pubmed: 31415841
J Neurosci Methods. 2020 Jul 15;341:108720
pubmed: 32416472
Front Oncol. 2022 Aug 01;12:884814
pubmed: 35978808
Am J Hum Genet. 2008 Apr;82(4):903-15
pubmed: 18355774
Dev Biol. 2006 Apr 1;292(1):174-88
pubmed: 16499899
Cancer Genet Cytogenet. 2001 May;127(1):30-3
pubmed: 11408061
Dev Dyn. 2009 Apr;238(4):875-86
pubmed: 19301400
Biotechniques. 2003 Feb;34(2):374-8
pubmed: 12613259
Cancer Res. 2000 Jul 15;60(14):3899-903
pubmed: 10919666
N Engl J Med. 2007 Sep 6;357(10):1054-6
pubmed: 17804857
Endocr Relat Cancer. 2018 Feb;25(2):R49-R58
pubmed: 29170162
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15785-90
pubmed: 16243968
Carcinogenesis. 2020 Sep 24;41(9):1253-1262
pubmed: 31784734
JAMA Oncol. 2016 Jul 1;2(7):922-8
pubmed: 27011036
Exp Biol Med (Maywood). 2018 Feb;243(4):327-333
pubmed: 29307282
J Clin Endocrinol Metab. 2011 Jan;96(1):E135-40
pubmed: 20881257
Cancer Cell Int. 2019 Feb 28;19:44
pubmed: 30858761
J Clin Endocrinol Metab. 2007 Aug;92(8):2938-43
pubmed: 17535989
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3663-7
pubmed: 11891324
Dev Cell. 2018 Dec 3;47(5):608-628.e6
pubmed: 30513303
Genes Dev. 2002 Oct 15;16(20):2650-61
pubmed: 12381664
Exp Mol Pathol. 2015 Oct;99(2):374-82
pubmed: 26112097

Auteurs

Fabio R Faucz (FR)

Section on Endocrinology & Genetics, Program on Developmental Endocrinology & Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America.

Anelia D Horvath (AD)

Department of Pharmacology and Physiology, School of Medicine and Health Sciences, The George Washington University, Washington, District of Columbia, United States of America.

Guillaume Assié (G)

Université Paris Cité, CNRS UMR8104, INSERM U1016, Institut Cochin, Paris, France.
Endocrine Department, Center for Rare Adrenal Diseases, AP-HP, Hôpital Cochin, Paris, France.

Madson Q Almeida (MQ)

Section on Endocrinology & Genetics, Program on Developmental Endocrinology & Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America.
Adrenal Unit, Laboratory of Molecular and Cellular Endocrinology LIM/25, Division of Endocrinology and Metabolism, University of Sao Paulo Medical School, São Paulo, Brasil.

Eva Szarek (E)

Section on Endocrinology & Genetics, Program on Developmental Endocrinology & Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America.

Sosipatros Boikos (S)

Section on Endocrinology & Genetics, Program on Developmental Endocrinology & Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America.

Anna Angelousi (A)

Section on Endocrinology & Genetics, Program on Developmental Endocrinology & Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America.

Isaac Levy (I)

Section on Endocrinology & Genetics, Program on Developmental Endocrinology & Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America.

Andrea G Maria (AG)

Section on Endocrinology & Genetics, Program on Developmental Endocrinology & Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America.

Ajay Chitnis (A)

Laboratory of Molecular Genetics, Section on Neural Developmental Dynamics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America.

Cristina R Antonescu (CR)

Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.

Rainer Claus (R)

Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany.

Jérôme Bertherat (J)

Université Paris Cité, CNRS UMR8104, INSERM U1016, Institut Cochin, Paris, France.
Endocrine Department, Center for Rare Adrenal Diseases, AP-HP, Hôpital Cochin, Paris, France.

Christoph Plass (C)

Division of Cancer Epigenomics, German Cancer Research Center, Heidelberg, Germany.

Charis Eng (C)

Genomic Medicine Institute, Lerner Research Institute, and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.

Constantine A Stratakis (CA)

Section on Endocrinology & Genetics, Program on Developmental Endocrinology & Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America.
Human Genetics & Precision Medicine, IMBB, Foundation for Research & Technology Hellas, Heraklion, Crete, Greece.
Research Institute, ELPEN, Pikermi, Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH